UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase II, Open-label, Single-arm, Multicenter Study to Assess the Activity and Safety of Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-positive NSCLC: ALNEO Trial

Clinical lung cancer, 2021-09, Vol.22 (5), p.473-477

2021

Volltextzugriff (PDF)

VATS right upper lobectomy after alectinib administration for ALK-positive lung adenocarcinoma

The Journal of the Japanese Association for Chest Surgery, 2021/05/15, Vol.35(4), pp.297-302

2021

Volltextzugriff (PDF)

Neoadjuvant alectinib in locally advanced lung adenocarcinoma with anaplastic lymphoma kinase rearrangement: case series and literature review

Anti-cancer drugs, 2023-11

2023

Volltextzugriff (PDF)

Identification of Crucial Genes and Signaling Pathways in Alectinib-Resistant Lung Adenocarcinoma Using Bioinformatic Analysis

Molecular biotechnology, 2023-12

2023

Volltextzugriff (PDF)

An investigation into solubility and dissolution improvement of alectinib hydrochloride as a third-generation amorphous solid dispersion

Journal of drug delivery science and technology, 2023-03, Vol.81, p.104259, Article 104259

2023

Volltextzugriff (PDF)

Is alectinib-induced elevation of creatine phosphokinase a predictive factor for response? Report of two cases and review of the literature

Anti-cancer drugs, 2021-04, Vol.32 (4), p.456-459

2021

Volltextzugriff (PDF)

Two Cases of ALK Fusion Gene-positive Lung Adenocarcinoma Treated with Brigatinib After Alectinib-induced Interstitial Lung Disease

Haigan, 2022/12/20, Vol.62(7), pp.1038-1043

2022

Volltextzugriff (PDF)

Osimertinib Overcomes Alectinib Resistance Caused by Amphiregulin in a Leptomeningeal Carcinomatosis Model of ALK-Rearranged Lung Cancer

Journal of thoracic oncology, 2020-05, Vol.15 (5), p.752-765

2020

Volltextzugriff (PDF)

Case report: BRAF A598-T599insV mutation as a potential resistance mechanism to alectinib in ALK-rearranged lung adenocarcinoma

Frontiers in oncology, 2022-11, Vol.12

2022

Volltextzugriff (PDF)

Absorption, distribution, metabolism and excretion (ADME) of the ALK inhibitor alectinib: results from an absolute bioavailability and mass balance study in healthy subjects

Xenobiotica, 2017-03, Vol.47 (3), p.217-229

2017

Volltextzugriff (PDF)

Identification of NMU as a potential gene conferring alectinib resistance in non-small cell lung cancer based on bioinformatics analyses

Gene, 2018-12, Vol.678, p.137-142

2018

Volltextzugriff (PDF)

Management of a Pregnant ALK-Positive Lung Cancer Patient With Alectinib-Induced Pneumonitis and Bilateral Globus Pallidus Necrosis Postpartum

Clinical lung cancer, 2024-01, Vol.25 (1), p.72-76

2024

Volltextzugriff (PDF)

Identification of a Novel HIP1-ALK Fusion Variant in Non–Small-Cell Lung Cancer (NSCLC) and Discovery of ALK I1171 (I1171N/S) Mutations in Two ALK-Rearranged NSCLC Patients with Resistance to Alectinib

Journal of thoracic oncology, 2014-12, Vol.9 (12), p.1821-1825

2014

Volltextzugriff (PDF)

A patient with ALK‐positive lung adenocarcinoma who survived alectinib‐refractory postoperative recurrence for 4 years by switching to ceritinib

Thoracic cancer, 2021-08, Vol.12 (15), p.2225-2228

2021

Volltextzugriff (PDF)

Development of Alectinib-Suspended SNEDDS for Enhanced Solubility and Dissolution

Pharmaceutics, 2022-08, Vol.14 (8), p.1694

2022

Volltextzugriff (PDF)

ALK陽性肺腺癌に対してアレクチニブ治療後に胸腔鏡下右上葉切除を施行した1例

日本呼吸器外科学会雑誌, 2021/05/15, Vol.35(4), pp.297-302

2021

Volltextzugriff (PDF)

Large Cell Neuroendocrine Carcinoma Harboring an Anaplastic Lymphoma Kinase (ALK) Rearrangement with Response to Alectinib

Internal Medicine, 2018/03/01, Vol.57(5), pp.713-716

2018

Volltextzugriff (PDF)

Feasibility and Safety of Neoadjuvant Alectinib in Pulmonary Invasive Mucinous Adenocarcinoma with ALK Rearrangement: Case Report and Literature Review

OncoTargets and therapy, 2021-01, Vol.14, p.5107-5113

2021

Volltextzugriff (PDF)

アレクチニブによる間質性肺疾患後にブリグチニブを使用したALK融合遺伝子陽性肺腺癌の2症例

肺癌, 2022/12/20, Vol.62(7), pp.1038-1043

2022

Volltextzugriff (PDF)

Is Elevation of Alkaline Phosphatase a Predictive Factor of Response to Alectinib in NSCLC?

Current oncology (Toronto), 2021-12, Vol.29 (1), p.173-177

2021

Volltextzugriff (PDF)

Intracranial Response of ALK+ Non-Small-cell Lung Cancer to Second-line Dose-escalated Brigatinib After Alectinib Discontinuation Due to Drug-induced Hepatitis and Relapse After Whole Brain Radiotherapy Followed by Stereotactic Radiosurgery

Clinical lung cancer, 2021-07, Vol.22 (4), p.e528-e532

2021

Volltextzugriff (PDF)

Efficacy and Resistance of ALK Inhibitors in Two Inflammatory Myofibroblastic Tumor Patients with ALK Fusions Assessed by Whole Exome and RNA Sequencing

OncoTargets and therapy, 2020-01, Vol.13, p.10335-10342

2020

Volltextzugriff (PDF)

Acquired L1196M ALK mutation in anaplastic lymphoma kinase‐positive anaplastic large cell lymphoma during alectinib administration

EJHaem, 2023-02, Vol.4 (1), p.305-308

2023

Volltextzugriff (PDF)

ALK‐rearranged lung adenocarcinoma resistant to alectinib with cauliflower gingival metastasis responds to brigatinib

Thoracic cancer, 2022-04, Vol.13 (7), p.1095-1097

2022

Volltextzugriff (PDF)

The Efficacy of Ceritinib for ALK-rearranged Non-small Cell Lung Cancer Previously Treated with Alectinib -an Analysis of Japanese and Global Phase I Studies

Haigan, 2017/06/20, Vol.57(3), pp.175-183

2017

Volltextzugriff (PDF)

1 – 25 von 29

Suche als RSS-Feed

Aktive Filter

ThemaAlectinib

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(22)
Mit Volltextzugriff
(25)

Publikationsform

Artikel
(29)

Sprache

Englisch
(23)
Japanisch
(8)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(21)
Science & Technology
(21)
Oncology
(14)
Humans
(12)
Alectinib Resistance
(9)
Female
(8)
Lung Neoplasms - Drug Therapy
(8)
Lung Neoplasms - Genetics
(7)
Lung Neoplasms - Pathology
(7)
Case Report
(6)
Lung Adenocarcinoma
(6)
Lung Cancer
(6)
Middle Aged
(6)
Mutation
(6)
Carbazoles - Therapeutic Use
(5)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(5)
Metastasis
(5)
Patients
(5)
Pharmacology & Pharmacy
(5)
Respiratory System
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase II, Open-label, Single-arm, Multicenter Study to Assess the Activity and Safety of Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-positive NSCLC: ALNEO Trial

VATS right upper lobectomy after alectinib administration for ALK-positive lung adenocarcinoma

Neoadjuvant alectinib in locally advanced lung adenocarcinoma with anaplastic lymphoma kinase rearrangement: case series and literature review

Identification of Crucial Genes and Signaling Pathways in Alectinib-Resistant Lung Adenocarcinoma Using Bioinformatic Analysis

An investigation into solubility and dissolution improvement of alectinib hydrochloride as a third-generation amorphous solid dispersion

Is alectinib-induced elevation of creatine phosphokinase a predictive factor for response? Report of two cases and review of the literature

Two Cases of ALK Fusion Gene-positive Lung Adenocarcinoma Treated with Brigatinib After Alectinib-induced Interstitial Lung Disease

Osimertinib Overcomes Alectinib Resistance Caused by Amphiregulin in a Leptomeningeal Carcinomatosis Model of ALK-Rearranged Lung Cancer

Case report: BRAF A598-T599insV mutation as a potential resistance mechanism to alectinib in ALK-rearranged lung adenocarcinoma

Absorption, distribution, metabolism and excretion (ADME) of the ALK inhibitor alectinib: results from an absolute bioavailability and mass balance study in healthy subjects

Identification of NMU as a potential gene conferring alectinib resistance in non-small cell lung cancer based on bioinformatics analyses

Management of a Pregnant ALK-Positive Lung Cancer Patient With Alectinib-Induced Pneumonitis and Bilateral Globus Pallidus Necrosis Postpartum

Identification of a Novel HIP1-ALK Fusion Variant in Non–Small-Cell Lung Cancer (NSCLC) and Discovery of ALK I1171 (I1171N/S) Mutations in Two ALK-Rearranged NSCLC Patients with Resistance to Alectinib

A patient with ALK‐positive lung adenocarcinoma who survived alectinib‐refractory postoperative recurrence for 4 years by switching to ceritinib

Development of Alectinib-Suspended SNEDDS for Enhanced Solubility and Dissolution

ALK陽性肺腺癌に対してアレクチニブ治療後に胸腔鏡下右上葉切除を施行した1例

Large Cell Neuroendocrine Carcinoma Harboring an Anaplastic Lymphoma Kinase (ALK) Rearrangement with Response to Alectinib

Feasibility and Safety of Neoadjuvant Alectinib in Pulmonary Invasive Mucinous Adenocarcinoma with ALK Rearrangement: Case Report and Literature Review

アレクチニブによる間質性肺疾患後にブリグチニブを使用したALK融合遺伝子陽性肺腺癌の2症例

Is Elevation of Alkaline Phosphatase a Predictive Factor of Response to Alectinib in NSCLC?

Intracranial Response of ALK+ Non-Small-cell Lung Cancer to Second-line Dose-escalated Brigatinib After Alectinib Discontinuation Due to Drug-induced Hepatitis and Relapse After Whole Brain Radiotherapy Followed by Stereotactic Radiosurgery

Efficacy and Resistance of ALK Inhibitors in Two Inflammatory Myofibroblastic Tumor Patients with ALK Fusions Assessed by Whole Exome and RNA Sequencing

Acquired L1196M ALK mutation in anaplastic lymphoma kinase‐positive anaplastic large cell lymphoma during alectinib administration

ALK‐rearranged lung adenocarcinoma resistant to alectinib with cauliflower gingival metastasis responds to brigatinib

The Efficacy of Ceritinib for ALK-rearranged Non-small Cell Lung Cancer Previously Treated with Alectinib -an Analysis of Japanese and Global Phase I Studies

Aktive Filter

Suchergebnisse filtern